SHIKARI® Q-ADA
The Matriks Biotek SHIKARI® Adalimumab ELISA Kit has been specially developed for the quantitative analysis of free Adalimumab in serum and plasma samples.
SHIKARI® S-ATA
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
20ul
70 min
Serum, plasma
96
10ng/mL
85-115%
1 year
Use of Adalimumab (Humira®) has been linked to the development of antibodies against the drug at various levels (in some cases to the point of neutralizing the treatment), possibly leading to severe complications. The SHIKARI® S-ATA ELISA Kit provides a tool for easily monitoring anti-Adalimumab levels and exploring ways of limiting problematic immunoresponses to this drug.
Calibration Curve
SHIKARI® Q-ADA & S-ATA
Adalimumab (Humira®)
Enzyme immunoassay for the quantitative determination of free Adalimumab (Humira®) in serum and plasma with confirmation
Enzyme immunoassay for the determination of antibodies to Adalimumab in serum and plasma
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
20ul
140 min
Serum, plasma
96
30ng/ml
85-115%
1 year
Q-ADAv1 : $878.00                                            Lead time: 1-2 weeks
S-ATAv1 (w/o Confirmation): $878.00            
S-ATAv2 (w/ Confirmation)  : $943.00 
Calibration Curve
S-ATAv1


S-ATAv2
Peer Reviewed Journals:

Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.**

Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. Sep;43(9):1018-23, 2016.**

Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. **

Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. **

Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **
** Open Access 
.....................................................
Lead time: 1-2 weeks   
.....................................................
Drug Measurement
Anti-drug Antibody Measurement
Quantitative
Quantitative
Qualitative
Semi-Quantitative
Adalimumab (Humira®)
Anti TFN-alpha Blockers
Q-ADA
(Free)

#TR-ADAv1
S-ATAv1
(Free)

#TR-AADAv1
S-ATAv4 DUO
(Free & Total)

#TR-AADAv4
S-ATAv2


#TR-AADAv2
Iwai North America Inc.

541 Taylor Way Suite# 4
 San Carlos, CA 94070
 Phone : (650) 486-1541
Fax : (650) 394-8638
 Open weekdays 9 AM-6 PM (PST)
.........................................................................................................................................................................................................................................................
SHIKARI® S-ATA DUO
Free and Total Anti drug Antibody monitoring have recently gained high importance along with measuring free drug from the patient samples. In order to make these measurements simple yet more informative, Matriks has produced SHIKARI® S-ATA DUO to measure Free and Total anti drug antibodies to Adalimumab simultaniously on the same plate. The kit is semi-quantitative and enables follow up of the patients to adjust the dose of the drug and/or frequency of administration
Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to adalimumab in serum and plasma.
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
10ul
95 min
Serum, plasma
96
250ng/ml
  -
1 year
S-ATAv4 (DUO): $943.00

S-ATAv4

Lead time: 1-2 weeks